Aktienanalyse zu Monopar Therapeutics Inc (MNPR)MNPRMonopar Therapeutics Inc

Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Monopar Therapeutics Inc is not a good buy right now due to its current price of $69.27, which is significantly below the analyst price target of $145 from Barclays. Additionally, the stock has a very low RSI of 17.804, indicating it is oversold, but the negative earnings trend with a forward P/E of 0 and a net income loss of -5,313,300 USD in Q2 2026 raises concerns about its financial health. The main risk is the continued negative earnings trend, with losses expected to persist in the coming quarters.